Thermo Fisher Scientific Improves Cancer Diagnostics for West of Scotland Regional Cytogenetics Service
News Feb 23, 2010
Thermo Fisher Scientific Inc. has announced that the West of Scotland Regional Cytogenetics Service has chosen the Thermo Scientific Varistain Gemini ES banding machine and Thermo Scientific ClearVue automated coverslipping machine for improved automation in the postnatal laboratory at its Department of Cytogenetics.
The Varistain Gemini ES is setting new standards for the efficiency of slide banding at the facility, reducing the slide-making and banding workload of the technical staff by nearly 50 percent.
In addition, the ClearVue solves the workflow hassles facing the laboratory, delivering the speed and precision that the postnatal division demands. The coverslipping machine ensures that each slide is uniform in both the placement of the coverslip and the depth of the mountant, improving the procedure.
The West of Scotland Regional Cytogenetics Service provides assistance to approximately three million people in western Scotland. The postnatal laboratory is using a full range of standard cytogenetic techniques and molecular cytogenetic technology to provide comprehensive chromosome analysis for both constitutional and acquired abnormalities.
The laboratory processes approximately 6,500 analyzes per year: nearly 2,800 of these are postnatal referrals. With such a high turnaround, the laboratory recognized that it needed to implement automated procedures to improve reporting times, quality and success rates.
Prior to installing the Thermo Scientific instrumentation, the postnatal laboratory experienced challenges with manual coverslipping and inconsistent speed in its manual banding process. The division needed an automated solution to increase throughput of blood samples, ensuring more efficient sample turnaround, slide preparation and reporting of results.
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE
5th International Congress on Epigenetics & Chromatin
Aug 22 - Aug 23, 2019
International Conference on e-Health and Healthcare Innovations
May 08 - May 09, 2019
4th Annual Congress on Nanomedicine and Drug Delivery
Apr 04 - Apr 06, 2019